The University of Missouri has unveiled an FDA-approved targeted radioactive medication known as Lutetium-177 PSMA therapy to address advanced metastatic prostate cancer.
Pluvicto® represents the branded radiopharmaceutical incorporating lutetium-177 (Lu-177), a radioisotope. The utilisation of Lutetium-177 PSMA therapy brings promise to individuals confronting advanced metastatic prostate cancer.
This therapy holds promise for individuals experiencing the ongoing progression of metastatic prostate cancer following prior interventions like chemotherapy and hormonal therapy.
The administration protocol consists of a series of six injections, strategically spaced six weeks apart. Remarkably, each injection is completed in less than 10 minutes, presenting a streamlined and efficient process.
Notably, this therapy stands out as it necessitates no additional medications, simplifying the treatment regimen for individuals undergoing this innovative approach.
This groundbreaking therapy offers substantial hope for patients grappling with the ongoing progression of prostate cancer following previous treatments.
